This study illustrates the feasibility of in vivo imaging of c-MET dynamics by detecting upregulation after c-MET-mediated erlotinib resistance, as well as downregulation of c-MET following HSP90-directed therapy using 89Zr-onartuzumab PET in human NSCLC xenograft-bearing mice. Here, MET is linked to non-small cell lung carcinoma.